Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA Impressive results in two proof-of-concept clinical trials reveal rapid response rate, repeated response following retreatment and excellent safety profile Cancer immunotherapy market is anticipated to grow to $145 billion by […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.